These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36556513)

  • 41. The different expression of glycogen phosphorylases in renal clear cell renal carcinoma and chromophobe renal carcinoma.
    Lu Y; Luo G; Zhu S; Wang X; Chen Y; Dong Z; Wang S; Ma J; Deng H; Wu D; Dong J
    Clin Proteomics; 2020; 17():7. PubMed ID: 32127786
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Imaging Mass Spectrometry Is an Accurate Tool in Differentiating Clear Cell Renal Cell Carcinoma and Chromophobe Renal Cell Carcinoma: A Proof-of-concept Study.
    Lu HC; Patterson NH; Judd AM; Reyzer ML; Sehn JK
    J Histochem Cytochem; 2020 Jun; 68(6):403-411. PubMed ID: 32466698
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The value of quantitative CT texture analysis in differentiation of angiomyolipoma without visible fat from clear cell renal cell carcinoma on four-phase contrast-enhanced CT images.
    You MW; Kim N; Choi HJ
    Clin Radiol; 2019 Jul; 74(7):547-554. PubMed ID: 31010583
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proteomic analysis of chromophobe renal cell carcinoma and benign renal oncocytoma biopsies reveals shared metabolic dysregulation.
    Carvalho LB; Jorge S; López-Fernández H; Lodeiro C; Dhir R; Campos Pinheiro L; Medeiros M; Santos HM; Capelo JL
    Clin Proteomics; 2023 Nov; 20(1):54. PubMed ID: 38017382
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aorta-Lesion-Attenuation-Difference (ALAD) on contrast-enhanced CT: a potential imaging biomarker for differentiating malignant from benign oncocytic neoplasms.
    Dhyani M; Grajo JR; Rodriguez D; Chen Z; Feldman A; Tambouret R; Gervais DA; Arellano RS; Hahn PF; Samir AE
    Abdom Radiol (NY); 2017 Jun; 42(6):1734-1743. PubMed ID: 28197683
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Value of clear cell likelihood score in differentiation between renal oncocytoma and clear cell renal cell carcinoma].
    Cui MQ; He B; Xu W; Hao YW; Ding XH; Wang S; Bai X; Liu BC; Ye HY; Wang HY
    Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3779-3785. PubMed ID: 36517429
    [No Abstract]   [Full Text] [Related]  

  • 47. Differentiating Oncocytic Renal Tumors from Chromophobe Renal Cell Carcinoma: Comparison of Peak Early-phase Enhancement Ratio to Clinical Risk Factors and Rater Predictions.
    Patel HD; Huai K; Elliott N; Thorson DL; Rac G; Picken MM; Quek ML; Bova D; Gupta GN
    Eur Urol Open Sci; 2022 Dec; 46():8-14. PubMed ID: 36506255
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Application of diffusion kurtosis tensor MR imaging in characterization of renal cell carcinomas with different pathological types and grades.
    Zhu J; Luo X; Gao J; Li S; Li C; Chen M
    Cancer Imaging; 2021 Mar; 21(1):30. PubMed ID: 33726862
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma.
    Amin J; Xu B; Badkhshan S; Creighton TT; Abbotoy D; Murekeyisoni C; Attwood KM; Schwaab T; Hendler C; Petroziello M; Roche CL; Kauffman EC
    Clin Cancer Res; 2018 Aug; 24(16):3898-3907. PubMed ID: 29752278
    [No Abstract]   [Full Text] [Related]  

  • 50. Differentiation of Clear Cell Renal Cell Carcinoma from other Renal Cell Carcinoma Subtypes and Benign Oncocytoma Using Quantitative MDCT Enhancement Parameters.
    Moldovanu CG; Petresc B; Lebovici A; Tamas-Szora A; Suciu M; Crisan N; Medan P; Buruian MM
    Medicina (Kaunas); 2020 Oct; 56(11):. PubMed ID: 33126571
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparative Analysis for the Distinction of Chromophobe Renal Cell Carcinoma from Renal Oncocytoma in Computed Tomography Imaging Using Machine Learning Radiomics Analysis.
    Alhussaini AJ; Steele JD; Nabi G
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892868
    [No Abstract]   [Full Text] [Related]  

  • 52. Subtype Differentiation of Small (≤ 4 cm) Solid Renal Mass Using Volumetric Histogram Analysis of DWI at 3-T MRI.
    Li A; Xing W; Li H; Hu Y; Hu D; Li Z; Kamel IR
    AJR Am J Roentgenol; 2018 Sep; 211(3):614-623. PubMed ID: 29812980
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.
    Steffens S; Roos FC; Janssen M; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Junker K; Kuczyk MA; Schrader AJ;
    Virchows Arch; 2014 Oct; 465(4):439-44. PubMed ID: 25178561
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
    Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
    Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The quantitative evaluation of contrast-enhanced ultrasound in the differentiation of small renal cell carcinoma subtypes and angiomyolipoma.
    Liu H; Cao H; Chen L; Fang L; Liu Y; Zhan J; Diao X; Chen Y
    Quant Imaging Med Surg; 2022 Jan; 12(1):106-118. PubMed ID: 34993064
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of phase of enhancement on texture analysis in renal masses evaluated with non-contrast-enhanced, corticomedullary, and nephrographic phase-enhanced CT images.
    Nguyen K; Schieda N; James N; McInnes MDF; Wu M; Thornhill RE
    Eur Radiol; 2021 Mar; 31(3):1676-1686. PubMed ID: 32914197
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Histogram analysis of whole-lesion enhancement in differentiating clear cell from papillary subtype of renal cell cancer.
    Chandarana H; Rosenkrantz AB; Mussi TC; Kim S; Ahmad AA; Raj SD; McMenamy J; Melamed J; Babb JS; Kiefer B; Kiraly AP
    Radiology; 2012 Dec; 265(3):790-8. PubMed ID: 23175544
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Magnetic resonance diffusion kurtosis imaging in differential diagnosis of benign and malignant renal tumors.
    Fu J; Ye J; Zhu W; Wu J; Chen W; Zhu Q
    Cancer Imaging; 2021 Jan; 21(1):6. PubMed ID: 33413681
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor grade estımatıon of clear cell and papıllary renal cell carcınomas usıng contrast-enhanced MDCT and FSE T2 weıghted MR ımagıng: radıology-pathology correlatıon.
    Halefoglu AM; Ozagari AA
    Radiol Med; 2021 Sep; 126(9):1139-1148. PubMed ID: 34100169
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Juxtatumoral perinephric fat analysis in clear cell renal cell carcinoma.
    Gill TS; Varghese BA; Hwang DH; Cen SY; Aron M; Aron M; Duddalwar VA
    Abdom Radiol (NY); 2019 Apr; 44(4):1470-1480. PubMed ID: 30506142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.